<DOC>
	<DOCNO>NCT01106651</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety 2 different dos canagliflozin compare placebo old patient ( 55 80 year age ) type 2 diabetes mellitus ( T2DM ) inadequate control current diabetes treatment regimen .</brief_summary>
	<brief_title>A Safety Efficacy Study Canagliflozin Older Patients ( 55 80 Years Age ) With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Canagliflozin drug test see may useful treat patient diagnose type 2 diabetes mellitus ( T2DM ) . This randomize ( study drug assign chance ) , double-blind ( neither patient study doctor know name assign treatment ) , placebo-controlled , parallel-group , 3-arm ( 3 treatment group ) multicenter study determine efficacy , safety , tolerability canagliflozin ( 100 mg 300 mg ) compare placebo ( capsule look like treatment real medicine ) patient T2DM achieve adequate response current antihyperglycemic therapy control diabetes . Approximately 720 old ( 55 80 year age ) patient T2DM either antihyperglycemic agent receive treatment stable regimen antihyperglycemic agent ( ) inadequate glycemic ( blood sugar ) control receive daily treatment canagliflozin ( 100 mg 300 mg ) placebo capsule 104 week ( include 26 week double-blind treatment follow 78-week extension period ) . In addition , patient take stable dos antihyperglycemic agent ( ) take entry study duration study . Patients participate study approximately 108 week . During study , patient 's fasting blood sugar remain high despite treatment study drug , patient receive treatment antihyperglycemic agent ( rescue therapy ) consider clinically appropriate consistent local prescribe information . During treatment , patient monitor safety review adverse event , result laboratory test , measure bone health , 12-lead electrocardiogram ( ECGs ) , vital sign measurement , body weight , physical examination , self-monitored blood glucose ( SMGB ) measurement . The primary outcome measure study effect canagliflozin relative placebo hemoglobin A1c ( HbA1c ) 26 week treatment . Study drug take orally ( mouth ) daily first meal day unless otherwise specify . All patient take single-blind placebo capsule 2 week randomization . After randomization , patient take double blind canagliflozin ( 100 mg 300 mg ) match placebo 104 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>All patient must diagnosis T2DM may currently treat stable regimen antihyperglycemic agent ( ) Patients study must HbA1c &gt; =7 &lt; =10.0 % Patients must fast plasma glucose ( FPG ) &lt; 270 mg/dL ( 15 mmol/L ) History diabetic ketoacidosis , type 1 diabetes mellitus ( T1DM ) , pancreas beta cell transplantation , diabetes secondary pancreatitis pancreatectomy , severe hypoglycemic episode within 6 month screen</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Canagliflozin</keyword>
	<keyword>Placebo</keyword>
	<keyword>Hemoglobin A1c</keyword>
	<keyword>Bone</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
</DOC>